Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2/3 1

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 9NIH 9NETWORK 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 2Thoracic 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Smoldering Multiple Myeloma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Lung Neoplasms 1Down Syndrome 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 16Magnetic Resonance Spectroscopy 13Vincristine 8Dexamethasone 6Cyclophosphamide 6Radiotherapy 5Radiation 5Leucovorin 5Lenalidomide 5Doxorubicin 5Cisplatin 5Calcium Dobesilate 5dexamethasone acetate 4dexamethasone 21-phosphate 4daratumumab 4auricularum 4X-Rays 4Standard of Care 4Radiotherapy, Conformal 4Practice Guidelines as Topic 4Etoposide 4Cytarabine 4Bortezomib 4Biopsy 4pegaspargase 3Taxes 3Radiotherapy, Intensity-Modulated 3Radiosurgery 3Prednisone 3Platinum 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
NETWORK × dexamethasone acetate × 30 days × Clear all
NCT01190930 2026-05-28

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

Children's Oncology Group

Phase 3 Completed
9,350 enrolled 51 charts
LymphoidOther hematologic neoplasm

Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05096663 2026-05-18

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2/3 Active not recruiting
82 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03937635 2026-05-15

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Eastern Cooperative Oncology Group

Phase 3 Recruiting
288 enrolled
Plasma cell

Smoldering Multiple Myeloma

NCT04566328 2026-05-15

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Eastern Cooperative Oncology Group

Phase 3 Recruiting
1,450 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡